WallStSmart

Baxter International Inc (BAX)vsBecton Dickinson and Company (BDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 95% more annual revenue ($21.92B vs $11.24B). BDX leads profitability with a 8.0% profit margin vs -8.5%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).

BAX

Buy

53

out of 100

Grade: C-

Growth: 4.7Profit: 3.5Value: 4.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.98

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BAX.

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAX1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

Areas to Watch

BAX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Altman Z-ScoreHealth
1.984/10

Grey zone — moderate risk

Debt/EquityHealth
1.603/10

Elevated debt levels

PEG RatioValuation
36.682/10

Expensive relative to growth rate

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BAX

The strongest argument for BAX centers on Price/Book.

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bear Case : BAX

The primary concerns for BAX are EPS Growth, Altman Z-Score, Debt/Equity. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Key Dynamics to Monitor

BAX profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.

BAX carries more volatility with a beta of 0.55 — expect wider price swings.

BAX is growing revenue faster at 8.0% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (61/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baxter International Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.

Visit Website →

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Want to dig deeper into these stocks?